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Relative hypothalamic-pituitary-adrenal axis dysfunction has been described as a common feature of
several dysfunctional pain syndromes, and its end hormone cortisol may thus constitute a protective fac-
tor against the development of chronic pain. We investigated the potential inﬂuence of experimentally
induced stresslike hypercortisolism on the induction of neurogenic hyperalgesia using 2 human surrogate
models: secondary hyperalgesia after intradermal capsaicin injection into the volar forearm, and percep-
tual windup in normal skin. In a double-blind, placebo-controlled, randomized, crossover study, a psy-
chophysical study was performed in 10 healthy subjects (median age 23 years) examining the effects
of 40 mg orally administered hydrocortisone. Numeric pain ratings were assessed for punctate pinprick
and light touch stimuli applied to the zone of secondary hyperalgesia adjacent to the capsaicin injection
and to the contralateral control side. In addition, visual analog ratings were assessed for repetitive pin-
prick stimulation of the noninjected arm. Hydrocortisone signiﬁcantly attenuated the late phase of cap-
saicin-induced pain by nearly 50%, and hyperalgesia to pinprick stimuli by 33% (both P < .05). Baseline
mechanical pain and dynamic mechanical allodynia remained unaltered. Temporal summation (windup)
to mechanical pain stimuli and electrically induced windup of second pain (tested in an independent
cohort of 10 other subjects) were also unchanged. The selective effects of hydrocortisone on pinprick
hyperalgesia but not pinprick pain suggest an antihyperalgesic rather than analgesic effect. The ﬁndings
suggest that hypothalamic-pituitary-adrenal axis reactivity might be an important mechanism in resil-
ience to dysfunctional pain syndromes.
 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
Dysfunctional pain disorders such as ﬁbromyalgia have been
shown to be associated with a blunting of the hypothalamic-pitu-
itary-adrenal axis, although inferring a causal relationship is pre-
cluded by the correlative and retrospective nature of the clinical
studies [77]. In a recent randomized, controlled study, we were
able to demonstrate that experimentally induced relative hypocor-
tisolism has the potential to augment temporal summation of pres-
sure pain and decrease mechanical pain detection thresholds, thus
supporting the assumption of a causal involvement of the hypotha-
lamic-pituitary-adrenal axis in modulation of pain sensitivity [38].
Consequently, cortisol might be considered a protective factor
and hypercortisolemia be assumed to delay or prevent pathological
pain processes. Interestingly, in diabetes mellitus, in which cortisol
levels considerably exceed the normal value (roughly 2 times), thefor the Study of Pain. Published by
berg.de (W. Magerl).prevalence of painful diabetic neuropathy is intriguingly low de-
spite peripheral neuropathy with negative symptoms such as
numbness as a major complication [2,50,65]. Although the exact
mechanisms of painful diabetic neuropathy are not fully under-
stood, spinal sensitization associated with increased inﬂammatory
mediator levels possibly promoted by local hyperglycemia and in-
duced by aldose reductase has been put forward, and could be
inhibited by the anti-inﬂammatory actions of cortisol [8]. Addition-
ally, painful diabetic neuropathy is characterized by a nocturnal
aggravation of pain, which would ﬁt the circadian rhythm of corti-
sol secretion [16].
To test whether neuroendocrinologic disturbances associated
with psychological distress are a risk factor for chronic pain, we
chose an indirect approach evaluating the protective effects of a
mild dose of hydrocortisone (synthetic cortisol) in a human surro-
gatemodel of neurogenic hyperalgesia induced by intradermal cap-
saicin injection, and perceptual correlates of electrical and
mechanical windup [23,40]. Those models were speciﬁcally chosen
because they induce sensory signs that are frequently observed inElsevier B.V. All rights reserved.
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ical allodynia, pinprick hyperalgesia, windup) and are supposed to
reﬂect some of the underlyingmechanisms such as small-ﬁber acti-
vation and central sensitization [4,27,36,47]. We gave healthy vol-
unteers either placebo or low-dose oral cortisol 90 min before
intradermal capsaicin injection. The cortisol dose was calculated
to mimic the cortisol response after, for example, major surgery in
previously healthy people. Thus, the placebo treatment in healthy
volunteers represents patients with dysfunctional reactivity of the
hypothalamic-pituitary-adrenal axis (no additional cortisol).
2. Methods
Here we report on 2 separate double-blind, placebo-controlled,
randomized, crossover trials analyzing the effects of hydrocorti-
sone treatment on pain processing realized in 2 completely distinct
subject samples undergoing different provocations (ie, the capsai-
cin model and mechanically induced windup in study 1, and elec-
trically induced windup in study 2). In study 1, the inﬂuence of a
supraphysiological but intermediate therapeutic dose of hydrocor-
tisone (40 mg orally) on changes of nociceptive sensibility (second-
ary hyperalgesia and dynamic mechanical allodynia) induced by
the selective C-ﬁber excitant capsaicin, as well as on perceptual
windup evoked by repeated punctate mechanical stimulation
was assessed [46,81]. In study 2, hydrocortisone effects on tempo-
ral summation of electrically induced and C-afferent-mediated sec-
ond pain were examined in supplementary experiments [55].
2.1. Subjects
Experiments of study 1 were performed on 10 healthy volun-
teers (median age 23 years; range 20–42 years); those of study 2
were performed on 10 other participants aged between 19 and
22 years (median age 20 years). All participants of study 1 were
right-handed, whereas in study 2, 3 participants showed left-hand-
edness or ambidexterity (assessed with the Edinburgh Handedness
Inventory) [51]. Subjects were free of dermatological disorders or
skin lesions. Persons with diabetic syndromes or gastroenteropa-
thies, or with renal, hepatic, or cardiovascular dysfunction were ex-
cluded. In addition, predeﬁned exclusion criteria comprised
pregnancy, chronic pain, and immunological disorders. No analge-
sics or antibiotics were administered 24 h before the start of each
session. Each subject participated in 2 experimental sessions (pla-
cebo and hydrocortisone condition in a balanced order) with ran-
dom assignment to treatment order and had previously provided
informed consent. There were no dropouts. The experimental pro-
cedures, which are in accordance with the ethical guidelines of
International Association for the Study of Pain, were approved by
the local ethics committees [9].
2.2. Treatment
To mimic an acute physiological cortisol increase, a single dose
of 40 mg synthetic cortisol (Hydrocortisone; Hoechst) was admin-
istered orally. This dose is the most commonly used in human psy-
chosocial stress research [56]. For comparison, average daily
cortisol production is approximately 10 mg in healthy subjects,
and rises to roughly 50 mg/d in minor surgery and 75–150 mg/d
in major surgery, multiple trauma, or severe sepsis, with maximal
secretion amounting up to 400 mg in severe stress syndromes
[17,31,39,60]. The placebo consisted of coated lactose powder.
2.3. Induction and monitoring of hyperalgesia
In study 1, neurogenic hyperalgesia was triggered by intrader-
mal injection of 40 lg capsaicin (Sigma-Aldrich) dissolved in12.5 lL of 0.16% polyoxyethylene-sorbitan-monostearate (Tween
80; Fluka, Munich, Germany) in normal saline according to the pro-
tocol of Simone et al. [63], and sterilized by ﬁltration with Sarto-
pure GF2 ﬁlters (pore size 0.2 lm; Sartorius, Göttingen,
Germany). The sterilized capsaicin solution was prepared by a
medical technical assistant and injected into the right volar fore-
arm on half the distance between wrist and cubital fossa
(Fig. 1A). For injection, sterile and pyrogen-free syringes were used,
with a 30-gauge cannula introduced as horizontally and as super-
ﬁcially as possible into the skin. Before injection, the skin was
cleaned with a 70% isopropanol pad.
The subjective pain sensation elicited by capsaicin was esti-
mated on a visual analog scale (VAS; length 100 mm), with verbal
anchoring of the endpoints (‘‘no pain’’ and ‘‘maximum pain imag-
inable’’). Ratings were collected upon injection until 5 min after
injection (in intervals of 10 s for the ﬁrst minute, and of 30 s from
the second through the last minute).
Ten minutes after injection, the area of capsaicin-induced ery-
thema (ﬂare) was visually inspected and marked with a dermato-
logically tested marker pen. The surface boundaries were
transcribed onto a transparent sheet of acetate paper at the end
of the experimental session. For exact quantiﬁcation of the out-
lined area size, a digital polar planimeter (accuracy 0.2%) was used.
Secondary hyperalgesia to punctate stimuli was tested by
applying a series of 7 probes consisting of cylindrical stainless steel
wires (tip diameter 0.25 mm) mounted on plastic rods of different
weights (exerting pressure forces of 8, 16, 32, 64, 128, 256, or
512 mN; MRC Systems, Heidelberg, Germany), which could slide
freely within a handheld metal tube. Wire tips were ﬂattened to
avoid skin penetration. Quantitative sensory testing of dynamic
mechanical allodynia relied on light touch stimulation evoked by
short and gentle stroking at constant velocity (stroke length
1 cm) with a cotton wisp, a Q-tip, and a soft brush. Ziegler
et al. [81] provide further details and stimulus calibration.
The sensory testing was performed within a ring-shaped area at
a distance of 15 mm from the injection site (Fig. 1A) to avoid stim-
ulation at the zone of primary hyperalgesia. The corresponding
skin region of the contralateral arm served as control area.
Throughout the experimental session, the test and the control
arm were comfortably laid on an armrest. The subjective sensa-
tions resulting from pricking and touch stimulation were evaluated
on a numeric rating scale (NRS; 0  no pain, 100 maximal pain
imaginable).
Sensory testing was organized in blocks (approximate duration
30 min), each consisting of 5 test runs (duration 5 ± 1 min) com-
prising 10 stimulus presentations (7 pinprick stimuli and 3 light
touch stimuli), allowing for all of the stimuli described above to
be applied 5 times in quasirandomized sequence during a single
test block. Stimulus duration was approximately 1 s, with an inter-
stimulus interval of approximately 10 s. Except for light touch
stimuli, and in order to preclude primary afferent sensitization or
fatigue effects, restimulation of an already stimulated spot was
avoided [40].
2.4. Induction and assessment of windup
In study 1, mechanically induced windup of pain sensation was
characterized on randomly assigned spots of the nondominant vo-
lar forearm. The testing for mechanical windup was performed
during the pauses between the hyperalgesia testing blocks and
consisted of 5 trains of 10 repeated pinprick stimuli at constant
intensity (256-mN probe) with a repetition frequency of 1 Hz.
For accurate repetition timing, the experimenters followed audio-
metronome tact beats. Subjects were asked to provide a separate
pain rating for every single stimulus presentation on a VAS identi-
cal to the one for the assessment of capsaicin-evoked pain.
Fig. 1. Schematic representations of experimental setup (study 1) and design (study 2). (A) Injection site for capsaicin (X), area for testing of secondary hyperalgesia and
dynamic mechanical allodynia (concentric circles), and schematized axon reﬂex ﬂare. Mechanical (punctate/tactile) stimuli were applied along the circumference of a circle
(radius 15 mm) surrounding the injection site. (B) Single test trial for the assessment of temporal summation induced by repetitive application of electrical stimuli consisting
of an initial single electric (rectangular waveform) pulse followed after a certain evaluation pause (interpulse interval <45 s) by a train of 8 identical shocks delivered at a
frequency of 1 Hz. VAS ratings were provided at the end of the single pulse (rating #A) and after termination of the pulse series (#B).
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approximately corresponds to the average size of receptive ﬁelds
of nociceptors [76].
In study 2, repetitive intracutaneous electric shocks (rectangu-
lar wave pulses; duration 20 ms) were delivered via a pulse gener-
ator connected to a constant current isolator to induce windup
[55]. For this purpose 2 sterilized 30-gauge needle electrodes were
inserted in parallel (distance 5 mm) into the thenar eminence of
the nondominant hand at half the distance between hypothenar
and wrist base. Before electrode penetration, the skin was cleaned
with an isopropanol pad. Subjects were grounded via wrist strap
electrodes.
Test trials consisted of an initial single electric pulse followed
after complete disappearance of aftersensations (interpulse inter-
val <45 s) by a series of 8 shocks delivered at a frequency of 1 Hz
(Fig. 1B). At the end of the single pulse and after termination of
the pulse series, subjects rated the respective pain intensities on
a handheld mechanical VAS (with graduated linear scale, 0–
100 units) [54]. Depending on current intensity, this stimulation
method induces an initial pricking pain experience, followed
1.5 s later by a second burning pain sensation. Estimates for both
types of sensation were obtained on separate test runs, with the
subjects being instructed to selectively attend either to ﬁrst or sec-
ond pain sensation.
To compensate for intersubject variability, the amplitude of the
electric rectangular pulses was adjusted at the beginning of each
session to a value where a distinct second pain sensation was iden-
tiﬁed and rated as approximately 20 ± 5 on the 0–100 VAS. The ad-
justed current level (range 4.0–6.0 mA) was then used throughout
the different testing conditions for a given experimental session.
2.5. Experimental protocol
Both studies consisted of 2 experimental sessions separated by
at least 6 days. A given experimental session in study 1 involved 5
sensibility testing and windup assessment blocks as described be-
fore (30 min duration each). The ﬁrst assessment period began
30 min before medication (premedication baseline; BL1). After
completion of BL1 testing, either hydrocortisone or placebo wasadministered with 200 mL of water. The second testing period
(postdrug/precapsaicin baseline; BL2) began 90 min after medica-
tion. It was instantly followed by estimation of spontaneous pain
and ﬂare induced by capsaicin (ie, 2 h after medication). Three fur-
ther blocks of sensibility testing followed at 30, 60, and 90 min
after injection (T1–3). The resorption time frame chosen here
was derived from pharmacokinetic analyses revealing that maxi-
mum concentrations are generally attained 1–1.4 h after oral
hydrocortisone administration [12,14,75].
The experimental sessions of the second study consisted of
baseline testing of electrically induced perceptual windup followed
by ingestion of hydrocortisone or placebo with 200 mL of water. A
second identical testing protocol was performed after a resorption
pause of 90 min. Baseline and postmedication testing comprised 8
trials each, corresponding to 4 test runs both for ﬁrst and for sec-
ond pain presented in alternating order and with an intertrial
interval of 3 min. Experimental factors were completely counter-
balanced across subjects, who were assigned at random to a spe-
ciﬁc treatment order, to control for potential carryover and
position effects related to pharmacodynamics and sensitization
procedures.
2.6. Data evaluation and statistical analysis
For statistical analysis the Statistica for Windows package (Stat-
soft; Hamburg, Germany) was used. Data were analyzed with re-
peated measures analysis of variance (ANOVA) and t test for
paired samples. For magnitude of effect estimation, Hays’s x2
and Cohen’s d were calculated, respectively. Alpha level was set
at P = .05. All data graphs were created with SigmaPlot (SPSS). Data
are represented as arithmetic mean (mean) ± standard error of the
mean (SEM). Sensitivity of the capsaicin model in our hands is such
that a 23% change in pain is detected at P < .01 and a 23% change in
hyperalgesia is detected at P < .05 with n = 10 (data from Ziegler
et al. [81], conﬁrmed by data from Magerl et al. [46], where a
32% change in pain was signiﬁcant at P < .005).
For capsaicin-induced pain, 3 parameters were extracted,
namely pain upon injection (peak capsaicin-induced pain), time
constant of pain decline, and average pain during the fourth and
G.P.N. Michaux et al. / PAIN
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for capsaicin-induced pain were calculated as the time to reach a
level of e1 (ie, 36.8%) of peak pain rating, which was linearly inter-
polated from the last pain rating just above and the ﬁrst pain rating
just below e1 level.
Pain ratings of suprathreshold pinprick stimuli were logarithmi-
cally transformed, with the purpose of normalizing and linearizing
the data. In order to avoid a loss of zero values due to log transfor-
mation, a constant of 0.1 was added to all raw data (ie, zero and
nonzero values) [3]. Stimulus-response (S/R) functions were de-
rived for punctate stimuli, with the corresponding slope computa-
tion based on the estimates of linear functions derived from
regression analysis.
For estimating the amount of temporal summation of pinprick
pain in study 1, windup data were normalized to the rating for
the initial stimulus in each train and were analyzed by 2-way re-
peated measures ANOVA with stimulus repetition and treatment
as factors. Additionally, perceptual windup ratios were calculated
for each test block as average NRS rating across ﬁfth to 10th stim-
ulus divided by the ﬁrst stimulus rating within a given stimulus
train. In study 2, temporal summation of ﬁrst and second pain elic-
ited by brief electrical stimulation was calculated as the ratio of
NRS8 to NRS1, wherein NRS1 refers to the rating in response to
the single pulse preceding each train and NRS8 to the last pulse
of the train of 8 electric shocks.
3. Results
3.1. Capsaicin-evoked pain and erythema
Capsaicin injection induced a strong pain sensation with a burn-
ing character. Pain ratings reached a maximum immediately after
injection and steadily decreased thereafter in an exponential fash-
ion that could be ﬁtted linearly in a semilogarithmic plot (Fig. 2A).
The peak pain rating after hydrocortisone treatment (95.5%) was
nearly identical to that after placebo (96.7%), and mean VAS ratings
arithmetically averaged over the whole testing period (0–5 min)
were highly correlated between both treatments (r = .96; P < .05).
However, mean capsaicin pain ratings were reduced by 15% from
41.8% to 35.6% by hydrocortisone (P < .05, Table 1). Statistical anal-
ysis of the time course of pain ratings revealed a signiﬁcant main
effect of treatment (F1,9 = 5.27; P < .05; effect size x2 = 0.18). As
can be seen in Figure 2A, this reduction became only apparent after
a certain latency (signiﬁcant time  treatment interaction,Fig. 2. Capsaicin-evoked pain and erythema. (A) Time course of pain sensation (estimate
capsaicin. Hydrocortisone administration signiﬁcantly reduced the area under the time c
(mean ± SEM; n = 10) estimated 10 min after injection was not affected by the glucocortF10,90 = 3.91; P < .001). Post hoc comparisons (Newman-Keuls test)
conﬁrmed that the pain reduction became signiﬁcant at 4 min after
the injection. Late phase ratings (average 4–5 min) were reduced
by approximately 50% by hydrocortisone (t1,9 = 2.53; P < .03; effect
size d = 0.79; Table 1). Additionally, under hydrocortisone the time
constant of the pain rating time course was signiﬁcantly shortened
compared to placebo (113 ± 19 vs 151 ± 30 s, P < .05). In all subjects
pain was still present at 5 min after injection but had completely
disappeared before the sensibility testing for hyperalgesia and allo-
dynia was initiated.
Capsaicin evoked a substantial erythema surrounding the injec-
tion site as a consequence of axon reﬂex–induced vasodilatation
[69]. Examination of the ﬂare size (Fig. 2B; Table 1) did not show
any difference between the placebo (30.8 ± 2.2 cm2) and hydrocor-
tisone conditions (30.0 ± 3.2 cm2; P = .65). Capsaicin-induced pain
(area under the receiver–operating characteristic curve) and areas
of ﬂare were not signiﬁcantly correlated (r = .13; P = .72).
3.2. Hyperalgesia
S/R functions for pinprick pain for the test site before and after
drug administration and after capsaicin injection are shown in
Fig. 3. The psychometric functions for the postdrug precapsaicin
period were best ﬁtted by a power function and did not differ be-
tween the 2 treatment conditions, as the slopes of the regression
functions plotted in double logarithmic space were nearly identical
(power function exponents/slopes 0.72 ± 0.06 vs 0.71 ± 0.04 for
placebo and hydrocortisone, respectively). After the capsaicin
injection, an upward shift of the corresponding S/R curves in com-
parison to the power functions for normal skin was observed, indi-
cating that capsaicin-induced pinprick hyperalgesia occurred
under both placebo and hydrocortisone treatment.
Hydrocortisone treatment, however, signiﬁcantly reduced post-
capsaicin pain ratings compared to placebo (F1,9 = 7.84; P < .04;
x2 = 0.26), with an average reduction of about 26% (Table 1, range
8–31%). Post hoc tests (Newman-Keuls) revealed that this antihy-
peralgesic effect only occurred at low to medium force levels. This
ﬁnding was conﬁrmed by an analysis of the slopes of the double
logarithmic regression functions. In the placebo condition, the
slope after capsaicin was much less than before because mostly
ratings to lower stimulus intensities were facilitated. This reduc-
tion in slope was signiﬁcantly less under hydrocortisone treatment
(from 0.71 ± 0.04 to 0.63 ± 0.06; D% = 10 ± 7%) than under placebo
(from 0.72 ± 0.06 to 0.54 ± 0.07; D% = 26 ± 7%; F1,9 = 2.77; P < .02;d on paper form VAS; mean ± SEM; n = 10) elicited by intradermal injection of 40 lg
ourse curve (P = .01) in average by 15%. (B) In contrast, area of neurogenic erythema
icoid.
Table 1
Summary of parameters (postdrug values) assessed in studies 1 and 2 and averaged hydrocortisone effect (as percentage change compared to placebo).
Parameter Placebo, mean ± SEM Hydrocortisone, mean ± SEM Change (D%) Pa
Capsaicin-induced pain
Mean rating (mm) 41.8 ± 6.4 35.6 ± 7.2 15% <.05 A*
Peak rating (mm) 96.7 ± 1.2 95.5 ± 1.6 1% .92 NK
Late phase average rating (mm) 18.5 ± 4.6 9.5 ± 2.1 49% .03 T*
Decay time constant (s) 151 ± 30 113 ± 19 25.0% .04 T*
Capsaicin-induced ﬂare (cm2) 30.8 ± 2.2 30.0 ± 3.2 2.5% .65 T
Pinprick-evoked pain (0–100)
Control site
Before capsaicin 1.5 ± 0.4 1.6 ± 0.6 +7% .97 NK
After capsaicin 1.6 ± 0.4 1.5 ± 0.6 7% .92 NK
Test site
Before capsaicin 1.7 ± 0.4 1.7 ± 0.6 0% .99 NK
After capsaicin 4.9 ± 0.9 3.6 ± 0.9 26% .04 NK*
Test/control
Before capsaicin 1.1 ± 0.1 1.1 ± 0.0 0% .88 NK
After capsaicin 3.7 ± 0.5 3.1 ± 0.4 16% .02 NK*
Hyperalgesia (% of baseline)b 424 ± 73 316 ± 42 25.5% .02 T*
Hyperalgesia (% increase vs baseline)b 324 ± 73 216 ± 42 33.3% .02 T*
Allodynia (incidence rate) 35% 34.7% 0.3%
Mechanical windup (% of predrug baseline)
Initial stimulus in trainc 121 ± 21 118 ± 14 2.5% .44 T
Plateau (ﬁfth–10th stimulus)c 247 ± 52 243 ± 42 1.5% .45 T
Ratio (train ﬁnal/single) 2.2 ± 0.3 2.5 ± 0.5 +14% .37 T
Electrical windup (% of predrug baseline)
Single stimulusc 99 ± 7 104 ± 8 +5.5% .56 T
Final stimulus in trainc 149 ± 14 153 ± 13 +3% .64 T
Ratio (train ﬁnal/single) 1.5 ± 0.1 1.5 ± 0.1 0%
a Statistical test is indicated as follows:
A, repeated measures ANOVA (main effect analysis); NK, repeated measures ANOVA (post hoc analysis; Newman-Keuls test); T, t test for paired samples.
b Normalized to postdrug/precapsaicin values.
c Normalized to predrug values (indicated in %).
* P < .05.
Fig. 3. S/R function for pinprick-evoked pain (mean ± SEM; n = 10). The S/R functions of pinprick pain were best ﬁtted by a power function (linearized in double logarithmic
coordinate system). Dashed lines refer to predrug and solid lines to postdrug measurements. Under placebo treatment (A), a substantial capsaicin-induced upward shift of the
S/R function (ie, hyperalgesia; fourfold increase) could be observed with a reduction in slope, whereas under hydrocortisone treatment (B), this upward shift was less
pronounced (ie, antihyperalgesia; increase by only a factor of 3.1) and the slope was unchanged (parallel shift). These ﬁndings suggest that the antihyperalgesic effect of
hydrocortisone predominated at low stimulus intensities.
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predominantly for those stimulus intensities that were most
strongly facilitated by capsaicin. This observation suggests a spe-
ciﬁc antihyperalgesic effect.
For analysis of the time course of pinprick-evoked pain, ratings
for all stimulus intensities were aggregated over each test run (ie,
over a 5 ± 1 min time window) and normalized to predrug values
(Fig. 4A,B; corresponding nonnormalized data are presented in Ta-
ble 1). Pain ratings to pinprick stimulation underwent a step in-
crease after capsaicin injection that was stable for the entireobservation period. Hydrocortisone attenuated pain ratings to pin
pricks in the capsaicin-induced secondary hyperalgesia zone by
26% vs placebo (averaged over the 90 min assessment period;
F1,9 = 2.59; P = .015; x2 = 0.15). This corresponded to a 33% reduc-
tion of hyperalgesia assessed as pain rating increase over baseline
(hydrocortisone 216 ± 42%; placebo 324 ± 73%, P < .05); thus, the
extent of hyperalgesia reduction by hydrocortisone is within the
range that is considered clinically meaningful [18].
In contrast, we did not detect any purely analgesic hydrocorti-
sone effects on pinprick pain because pain ratings for the test site
Fig. 4. Time course of pinprick-evoked pain for the control and test site. Each dot (mean ± SEM; n = 10) represents pain ratings aggregated over a 5 ± 1 min time window
(ratings were normalized to predrug values). (A) Under placebo treatment, pain ratings were slightly raised from the second testing point on, which may be attributed to
sensitization elicited by the repeated pinprick application. (B) Hydrocortisone treatment prevented this sensitizing effect and substantially attenuated secondary irritant-
induced hyperalgesia.
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hydrocortisone (Table 1). Moreover, pain ratings in the control area
did not differ between treatments at any point in time with differ-
ences between treatments ranging between 7% and +7%; all
P > .80; Table 1).
3.3. Dynamic mechanical allodynia
Applying light tactile stimuli to normal skin never elicited a per-
ceptible pain sensation. In contrast, dynamic mechanical allodynia
was seen in 7 out of 10 subjects and it was signiﬁcant in 4 subjects
(single subject statistic). For the other 3 of the 7 subjects, there was
only 1 painful rating per 45 tactile stimuli. However, manifestation
of allodynia was similar under both treatment conditions, with an
incidence of 35% for the placebo and 34.7% for the hydrocortisone
condition.
3.4. Perceptual windup
The analysis of the VAS ratings for repetitive pinprick stimula-
tion (Fig. 5A,B) by repeated measures ANOVA showed a signiﬁcant
stimulus repetition related increase of pain sensation under both
treatment conditions (F9,81 = 15.28; P < .0001; x2 = 0.87), but no
signiﬁcant treatment effect (P = .22), nor any interaction between
treatment condition and stimulus repetition (P = .26) Similarly,
temporal summation estimated as windup ratio did not differ be-
tween both conditions (Fig. 5C,D; Table 1). Windup ratios were
quasi identical before and after medication, namely with a factor
of 2.2 ± 0.3 vs 2.2 ± 0.3 for the placebo and 2.4 ± 0.3 vs 2.5 ± 0.5
for the hydrocortisone condition.
In study 2 in another group of subjects, intracutaneous electri-
cal shock presentation reliably produced pinprick-like ﬁrst and
burning-like second pain, with a retest reliability of r = .81
(P < .05) and an intraindividual variation coefﬁcient of 3% of the
mean (4.6 mA) for second pain thresholds. Descriptive analysis of
the data did not reveal any analgesic effect of hydrocortisone
administration because VAS ratings for second pain evoked by
the ﬁrst stimulus in each train did not vary between hydrocorti-
sone and placebo treatment (Table 1). Likewise, no diminution of
slow temporal summation relative to baseline could be observed,
as the mean ratios were very similar under the corresponding pla-
cebo and treatment conditions. On average, the postdrug temporal
summation was slightly increased, but did not differ between
hydrocortisone and placebo treatment (Fig. 5E,F; Table 1). In agree-
ment with the ﬁndings for second pain, no hydrocortisone effect
could be observed for ﬁrst pain (data not shown).4. Discussion
We observed an abbreviated time course and a reduction in the
late phase of capsaicin-induced pain by a mild dose of hydrocorti-
sone without any effects on the peak pain upon injection. Pinprick
pain was not inﬂuenced in normal skin, but pinprick hyperalgesia
after capsaicin was strongly attenuated to a degree that can be con-
sidered clinically meaningful. There was no effect on dynamic
mechanical allodynia nor on windup for mechanical or electrical
stimuli.
4.1. Antihyperalgesic, analgesic, or anti-inﬂammatory effects of
hydrocortisone
Previously, elevated cortisol levels during stress were found to
be associated with lower capsaicin-induced pain [44]. In the rodent
paw formalin test, systemic corticosterone led to suppression of
formalin-induced pain behavior speciﬁcally occurring during the
late phase implying a role in control of central sensitization
[26,62]. It is thus tempting to interpret our ﬁnding of a speciﬁc
attenuation of the late phase of capsaicin-induced pain also as indi-
cating an effect on central sensitization. The absence of an effect on
peak pain, however, may also either mean that a possible analgesic
efﬁcacy of hydrocortisone may be overcome by very strong stimuli
or simply be due to ceiling effects because pain ratings at capsaicin
injection were near maximal imaginable pain (96 of 100).
Efﬁcacy of corticosterone in the late phase of the formalin test
may also reﬂect inhibition of inﬂammatory mediators [73]. The hu-
man capsaicin injection model also reﬂects some aspects of inﬂam-
matory pain, namely TRPV1-mediated pain and neurogenic
inﬂammation [36]. The capsaicin-induced erythema, however,
was not reduced in our study, making it unlikely that peripheral
anti-inﬂammatory actions of hydrocortisone were responsible for
the observed effects. Other studies have shown that reductions of
capsaicin-induced erythema in humans and plasma extravasation
in animals occur only with much longer duration of topical gluco-
corticoid treatment [34,71].
In the ﬁrst-degree burn model of secondary hyperalgesia, sys-
temic dexamethasone reduced the size of the secondary hyperalge-
sia area (assessed with a stiff v. Frey probe) from 35 cm2 to 23 cm2,
without any effect on perceived pain during the initiating burn
[78]. Likewise, methylprednisolone led to a signiﬁcant reduction
of the area of secondary hyperalgesia, but no effect on pressure
pain threshold [68]. Topically applied glucocorticoids did not in-
duce any antihyperalgesic effects in the same model, suggesting
a predominantly central site of glucocorticoid action, consistent
Fig. 5. Mechanically and electrically induced windup of pain sensation in normal
skin. (A, B) VAS ratings (mean ± SEM; n = 10) for the estimation of the repeated
pinprick stimulation in normal skin (weight force 256 mN; repetition rate 1 Hz).
Postdrug values were slightly raised in comparison to the predrug reference values,
but did not differ between placebo and hydrocortisone treatment. Ratings were
normalized to the initial predrug VAS rating. (C, D) Pain summation estimated as
windup ratio for pinprick (deﬁned as the ratio of the ﬁrst to the average across the 6
last ratings; mean ± SEM; n = 10) was unaffected by glucocorticoid treatment. (E, F).
Similarly, temporal summation of second pain in response to trains of repeated
constant intensity electric shocks (repetition rate 1 Hz; mean ± SEM; n = 10) was
not altered by hydrocortisone pretreatment (see text for details on data
aggregation).
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sensitization [1,46,52,74].
The hypothesis that antihyperalgesic effects of glucocorticoids
may be due to an action within the CNS is further supported by
data from animal neuropathic pain models, where systemic or epi-
dural/intrathecal glucocorticoid application inhibited the develop-
ment and maintenance of mechanical hyperalgesia/allodynia
related to peripheral nerve injury [72,80]. Even in a classical
inﬂammatory pain model (carrageenan-induced inﬂammation),
there is evidence that reversal of muscle hyperalgesia by exoge-
nous glucocorticoids might be related to spinal glucocorticoidreceptor activation leading to prolonged GABAA receptor–mediated
synaptic currents [32,53].
Our ﬁnding of a predominant antihyperalgesic effect of hydro-
cortisone on pinprick hyperalgesia is reminiscent of the differential
effectiveness of corticotropin-releasing hormone (CRH), which
may at least partly be mediated by endogenous glucocorticoids
[42]. Intravenous CRH application reduced pain affect and pain
intensity in a clinical model with peripheral and central sensitiza-
tion (postsurgical dental pain), but had no effect on heat pain
thresholds and on ratings to suprathreshold thermal stimuli in nor-
mal nonsensitized skin [22,43].
4.2. Possible mechanisms of antihyperalgesic action of glucocorticoids
The rapid onset of action in the present study (90 min) may be
explained by nongenomic mechanisms, which have recently been
identiﬁed in the nervous system [45,48,82]. Nongenomic action
of glucocorticoids can operate within minutes and is mediated by
binding to speciﬁc glucocorticoid membrane receptors, and may
lead to rapid suppression of intracellular signal cascades—for
example, mediated via phospholipase A2 [11]. Recently, low-dose
hydrocortisone inhibited a different measure of central nervous
plasticity, prepulse inhibition in a fast onset and rapidly declining
time course, which could not be explained by genomic effects [58].
Generally, however, genomic effects can not be fully excluded be-
cause they also start already within 10–30 min and may suppress,
for example, the NF-jB complex [66].
As glucocorticoid receptors have been localized on nerve cells
in dorsal root and trigeminal ganglia, it may thus be hypothesized
that hydrocortisone exerted a suppressive effect via glucocorti-
coid receptors on dorsal root ganglion neurons or presynaptic
endings [10,13]. Concordant with this speculation, synthetic cor-
ticosteroids were found to suppress ectopic discharges from
experimental neuromas as well as the neurotransmission in C ﬁ-
bers [15,28].
Suppression of secondary hyperalgesia was only assessed 30–
90 min after its induction. This time window may already sufﬁce
to allow for a potential contribution of glial activation because in
another model of injury-induced hyperalgesia (ie, subcutaneous
formalin injection in rats), it has been shown that the expression
of the microglial MAP kinase isoform p38b, which mediated this
form of hyperalgesia, already peaked at 15 min after injection
[57,61,70]. Thus, antihyperalgesia due to hydrocortisone in our
study may also reﬂect a glucocorticoid action on immune cells
within the CNS. Such a mode of action would be particularly
interesting because in the same human surrogate model, the
NMDA receptor antagonist neramexane exerted analgesic effects
in both normal and hyperalgesic skin, thus lacking speciﬁc anti-
hyperalgesic efﬁcacy [35]. The lack of effect of hydrocortisone on
windup suggests that the mechanisms of that short-term plastic-
ity in the spinal cord have little in common with the more
prolonged sensitization responsible for secondary hyperalgesia
[79].
Intriguingly, reducing effects on detection and discrimination
thresholds by exogenous hydrocortisone have been observed for
other exteroceptive sensory systems (audition and gustatory
sense) with comparable or even lower dosage than used in our
study as well as with enhanced cortisol secretion provoked by
experimental psychological stress [5,7,19,20]. In contrast to other
sensory systems, a small rise in cortisol levels as during stress
thus seems to selectively inhibit pathophysiological processes
involved in the enhancement of pain sensitivity, while conserv-
ing normal signaling capacity of the nociceptive system. Analge-
sic efﬁcacy of glucocorticoids seems to require higher cortisol
levels, as has been proven in several acute surgery pain forms
[59,64].
G.P.N. Michaux et al. / PAIN

153 (2012) 420–428 4274.3. Clinical implications
Our data suggest that systemic administration of glucocorti-
coids can prevent hyperalgesia without blocking acute pain and
may thus be beneﬁcial in clinical situations of enhanced pain sen-
sitivity. Administration of high-dose dexamethasone after lumbar
disk surgery suppressed movement-evoked pain; this sign can be
considered as an indicator of central sensitization to mechanical
stimuli and it was reduced by approximately 25%—that is, similar
to the reduction of secondary hyperalgesia in our data [29]. Other
studies on hypoalgesia by perioperative glucocorticoid administra-
tion during minor surgical procedures are inconclusive with regard
to the proposed antihyperalgesic speciﬁcity, as hyperalgesia was
not speciﬁed as a therapeutic endpoint [6,41,49]. In these condi-
tions, clinical pain-reductive glucocorticoid efﬁcacy is commonly
associated with antiedematous effects [24].
Transient partial pain relief by systemic glucocorticoids has
been observed for complex regional pain syndromes as an example
of dysfunctional pain syndromes [33]. As an example of neuro-
pathic pain syndromes, Kotani et al. found an effect of intrathecal
glucocorticoid injections on intensity and area of dynamic
mechanical allodynia in postherpetic neuralgia [37]. The same
low dose of hydrocortisone as used in our experiments signiﬁ-
cantly improved sensory leg discomfort in patients with restless
legs syndrome, a neurological disease characterized by substantial
hyperalgesia to the same pinprick stimuli used in our experimental
model of hyperalgesia [25,67].
4.4. Conclusions
In the studies presented here, we demonstrate a causal inﬂu-
ence of systemic application of hydrocortisone (synthetic cortisol)
in a surrogate model of neurogenic hyperalgesia, indicating a po-
tential implication of adrenocortical activity in speciﬁc modulation
of hyperalgesic states, which is conceivable as a nonopioid form of
stress-induced hypoalgesia [21,36]. Hypercortisolemia thus would
constitute a protective factor against neurogenic pain, which
speaks in favor of perisurgical hydrocortisone supplementation
as prophylaxis of pain chronicity, whereas hypocortisolism may
be considered a risk factor for chronic pain [30,60].
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